文献速递心力衰竭与心肌病

丝氨酸生物合成作为扩张型心肌病的新型治疗靶点

Serine biosynthesis as a novel therapeutic target for dilated cardiomyopathy.
PubMed 文献 · Eur Heart J · 2022-01-01

该研究利用携带TNNT2基因突变(p.R183W)的患者来源诱导多能干细胞分化的心肌细胞(iPSC-CMs)建立扩张型心肌病(DCM)体外模型,通过小分子激酶抑制剂无偏表型筛选发现Gö 6976与SB 203580联合治疗可挽救多种基因突变所致DCM iPSC-CMs的收缩功能障碍,机制上通过ATF4依赖的丝氨酸生物合成途径改善代谢和线粒体呼吸缺陷。

要点

  • Gö 6976与SB 203580联合治疗可挽救多种基因突变所致DCM iPSC-CMs的收缩功能障碍。
  • 联合治疗上调丝氨酸、甘氨酸和一碳代谢酶基因表达,增加葡萄糖来源的丝氨酸和甘氨酸水平。
  • 联合治疗改善线粒体呼吸缺陷,增加三羧酸循环代谢物和ATP水平,机制依赖ATF4及其下游PHGDH和TRIB3。

核心结论

  • 调控丝氨酸生物合成信号可能成为遗传性DCM的基因型不可知的新型治疗策略。

研究设计与样本

  • 利用携带TNNT2基因突变(p.R183W)的患者来源iPSCs和CRISPR基因组编辑建立DCM体外模型,并在此模型上进行小分子激酶抑制剂无偏表型筛选。

主要发现

  • Gö 6976和SB 203580联合治疗挽救了携带TNNT2、TTN、LMNA、PLN、TPM1、LAMA2等多种基因突变的DCM iPSC-CMs的收缩功能障碍。
  • 联合治疗上调丝氨酸、甘氨酸和一碳代谢酶基因表达,显著增加DCM iPSC-CMs内葡萄糖来源的丝氨酸和甘氨酸水平。
  • 联合治疗挽救了DCM iPSC-CMs的线粒体呼吸缺陷,并增加三羧酸循环代谢物和ATP水平。
  • DCM表型的挽救由ATF4及其下游效应基因PHGDH(丝氨酸生物合成途径关键酶)和TRIB3介导。

临床怎么用

  • 该研究提示调控丝氨酸生物合成通路可能作为遗传性DCM的潜在治疗靶点,但尚未进入临床验证阶段。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: Genetic dilated cardiomyopathy (DCM) is a leading cause of heart failure. Despite significant progress in understanding the genetic aetiologies of DCM, the molecular mechanisms underlying the pathogenesis of familial DCM remain unknown, translating to a lack of disease-specific therapies. The discovery of novel targets for the treatment of DCM was sought using phenotypic sceening assays in induced pluripotent stem cell-derived cardiomyocytes (iPSC-CMs) that recapitulate the disease phenotypes in vitro. METHODS AND RESULTS: Using patient-specific iPSCs carrying a pathogenic TNNT2 gene mutation (p.R183W) and CRISPR-based genome editing, a faithful DCM model in vitro was developed. An unbiased phenotypic screening in TNNT2 mutant iPSC-derived cardiomyocytes (iPSC-CMs) with small molecule kinase inhibitors (SMKIs) was performed to identify novel therapeutic targets. Two SMKIs, Gö 6976 and SB 203580, were discovered whose combinatorial treatment rescued contractile dysfunction in DCM iPSC-CMs carrying gene mutations of various ontologies (TNNT2, TTN, LMNA, PLN, TPM1, LAMA2). The combinatorial SMKI treatment upregulated the expression of genes that encode serine, glycine, and one-carbon metabolism enzymes and significantly increased the intracellular levels of glucose-derived serine and glycine in DCM iPSC-CMs. Furthermore, the treatment rescued the mitochondrial respiration defects and increased the levels of the tricarboxylic acid cycle metabolites and ATP in DCM iPSC-CMs. Finally, the rescue of the DCM phenotypes was mediated by the activating transcription factor 4 (ATF4) and its downstream effector genes, phosphoglycerate dehydrogenase (PHGDH), which encodes a critical enzyme of the serine biosynthesis pathway, and Tribbles 3 (TRIB3), a pseudokinase with pleiotropic cellular functions. CONCLUSIONS: A phenotypic screening platform using DCM iPSC-CMs was established for therapeutic target discovery. A combination of SMKIs ameliorated contractile and metabolic dysfunction in DCM iPSC-CMs mediated via the ATF4-dependent serine biosynthesis pathway. Together, these findings suggest that modulation of serine biosynthesis signalling may represent a novel genotype-agnostic therapeutic strategy for genetic DCM.

来源:Eur Heart J,查看原文。版权归原作者所有。

引用

  1. Perea-Gil I, Seeger T, Bruyneel AAN, et al. Serine biosynthesis as a novel therapeutic target for dilated cardiomyopathy. Eur Heart J. 2022. PMID: 35728000. doi:10.1093/eurheartj/ehac305

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。